BCM
IOVA icon

Brookstone Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Brookstone Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94K Sell
22,607
-55
-0.2% -$209 ﹤0.01% 1285
2026
Q1 		$79.5K Sell
22,662
-21
-0.1% -$67 ﹤0.01% 1185
2025
Q4 		$61.9K Sell
22,683
-238
-1% -$551 ﹤0.01% 1152
2025
Q3 		$49.7K Buy
22,921
+10
+0% +$24 ﹤0.01% 1125
2025
Q2 		$39.4K Sell
22,911
-16
-0.1% -$40 ﹤0.01% 1053
2025
Q1 		$76.3K Buy
22,927
+2,344
+11% +$12.1K ﹤0.01% 1000
2024
Q4 		$152K Buy
20,583
+528
+3% +$4.89K ﹤0.01% 963
2024
Q3 		$188K Buy
20,055
+6,120
+44% +$58K ﹤0.01% 971
2024
Q2 		$125K Buy
+13,935
New +$149K ﹤0.01% 931

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Brookstone Capital Management's IOVA Position: Q2 2026 in Review

Brookstone Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 0.24% in Q2 2026, selling an estimated $209 and leaving 22,607 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #1285.

Brookstone Capital Management first reported a position in IOVA in Q2 2024 and has held it in 9 quarters since. The position peaked at $188K in Q3 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Brookstone Capital Management held 22,607 shares of Iovance Biotherapeutics worth $94K as of Q2 2026.
  • Brookstone Capital Management sold 55 Iovance Biotherapeutics shares in Q2 2026, an estimated $209.
  • Iovance Biotherapeutics made up ﹤0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #1285 holding.
  • Brookstone Capital Management first reported a position in Iovance Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
  • Brookstone Capital Management's Iovance Biotherapeutics position peaked at $188K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.